Regeneron Pharmaceuticals shared positive results from the company’s Phase III trial of a candidate drug for children with homozygous familial hypercholesterolemia (HoFH), a rare, life-threatening condition characterized by elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD.
New Inclisiran Analysis Evaluated LDL-C Reduction Across Individual Patient
Analysis, Atherosclerotic Cardiovascular Disease (ASCVD), Clinical Trials, Data, Elevated Low-Density Lipoprotein Cholesterol (LDL-C), European Medicines Agency (EMA), European Society of Cardiology (ESC) Congress, FDA, Hyperlipidemia, Placebo, Post-Hoc Analysis, Primary Hyperlipidemia, R&D, Small-Interfering RNA (siRNA) ClassNovartis announced results from a post-hoc analysis of pooled data from the Phase III ORION-10 and -11 trials evaluating the individual responses of patients on low-density lipoprotein cholesterol (LDL-C) reduction with inclisiran, a first-in-class investigational treatment for hyperlipidemia in adults.
Novo Nordisk is expanding the company’s presence in treating kidney disease with the acquisition of U.S.-based Corvidia Therapeutics for $2.1 billion.
The U.S. Food and Drug Administration approved Ann Arbor, Michigan-based Esperion’s Nexlizet (bempedoic acid and ezetimibe) for lowering LDL cholesterol.
Esperion’s Bemopedoic Acid Treatments Hit the Mark in Two Studies
"Bad" LDL Cholesterol, Atherosclerotic Cardiovascular Disease (ASCVD), Clinical Data, Clinical Studies, Clinical Trials, European Society of Cardiology (ESC) Congress, FDA, Marketing Authorization Applications, New Drug Applications, R&D, StatinsAnn Arbor, Mich.-based Esperion Therapeutics reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.